Ankyra Therapeutics Announces Promising Preclinical Data on ANK-101, a Novel Anchored Immune Medicine, in Combination with Cytotoxic Chemotherapy in Head and Neck Cancer Model streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First-in-class anchored IL-12 immunotherapy mANK-101 shows tumor growth delay in murine models as a monotherapy and in combination with platinum and anti-PD-1Data presented at the Society for Immunotherapy of Cancer in San Diego pave the way for ANK-101 as combination therapyCAMBRIDGE, Mass. (BUSINESS WIRE) Ankyra.
First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicityHuman ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies in 2024CAMBRIDGE, Mass. (BUSINESS WIRE) Ankyra Therapeutics, a pre-clinical stage biotechnology com.
First-in-class anchored IL-12 immunotherapy increases immune cell infiltration into tumors while decreasing systemic toxicity Human ANK-101, an IL-12- based anchored immunotherapy, will begin Phase 1 clinical studies